We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AD Biomarkers in Ocular Fluid Indicate Dementia Risk

By LabMedica International staff writers
Posted on 25 Mar 2019
Measuring levels of amyloid-beta and tau proteins in the eye's vitreous humor has been suggested as means to detect dementia at an early stage in individuals at risk for Alzheimer's disease (AD).

Investigators at the Boston Medical Center (MA, USA) determined levels of amyloid-beta (Abeta) and tau protein in human vitreous humor and evaluated the clinical predictive role of these proteins as early diagnostic markers of AD.

For this study, vitreous humor samples from 80 eyes were measured quantitatively for Abeta42, pTau, and tTau. More...
Linear regression was used to test associations between AD biomarker levels, Mini-Mental State Exam (a baseline cognitive test), and serum apolipoprotein E (APOE) allele status, with adjustment for age, sex, and education level of patients.

Results revealed that patients with poor cognitive function had significantly lower vitreous humor levels of the AD-related biomarkers Abeta40, Abeta42, and tTau. Levels of these biomarkers did not correlate with underlying eye conditions, suggesting their specificity in association with cognitive change. This was perhaps the first study to correlate cognition with AD-related proteins in the vitreous humor. Results suggested that ocular proteins may have a role for early dementia detection in individuals at risk for AD.

"This is a great step in discovering the eye's potential role in diagnosing preclinical Alzheimer's disease, and further study is needed comparing protein biomarkers in the eye with more in-depth neurological testing," said senior author Dr. Manju Subramanian, associate professor of ophthalmology at Boston Medical Center.

The study was published in the March 8, 2019, online edition of the Journal of Alzheimer's Disease.

Related Links:
Boston Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.